Prostate Cancer Diagnosis and Staging

A step by step guide to Prostate Cancer procedure steps, including PSA screening, mpMRI, and biopsy methods for accurate diagnosis and staging.

Diagnosis and Staging of Prostate Cancer

Accurate diagnosis and staging are the cornerstones of effective prostate cancer care, especially for international patients seeking world‑class treatment at Liv Hospital. By precisely identifying the presence of cancer and determining how far it has spread, clinicians can tailor therapy to each individual’s disease biology and personal goals. In Europe, prostate cancer accounts for roughly one in five new cancer diagnoses in men, and early, accurate staging dramatically improves long‑term outcomes. This page walks you through every step of the diagnostic pathway—from blood tests and biopsies to advanced imaging and risk‑group classification—so you understand what to expect when you choose Liv Hospital for your care.

Whether you have been referred after an elevated PSA, experienced urinary symptoms, or are pursuing a routine health check‑up, our multidisciplinary team uses the latest evidence‑based protocols to ensure that every piece of information is captured accurately. The following sections detail the laboratory, imaging, and pathological tools we employ, explain how they fit into internationally recognized staging systems, and illustrate how these results shape a personalized treatment plan.

Comprehensive Laboratory Evaluation

The first step in diagnosis and staging begins with a thorough laboratory work‑up. Blood tests not only confirm the suspicion of prostate cancer but also provide baseline data essential for treatment planning and monitoring.

Key Blood Markers

• Prostate‑specific antigen (PSA): The most widely used biomarker; trends over time help differentiate aggressive disease from indolent tumors.
• Free‑to‑total PSA ratio: Improves specificity when total PSA levels are in the borderline range (4–10 ng/mL).
• Alkaline phosphatase and calcium: Indicators of possible bone metastasis.
• Lactate dehydrogenase (LDH): May reflect tumor burden in advanced disease.

When to Perform Additional Blood Tests

Beyond PSA, we assess hormonal status and organ function to prepare for potential systemic therapies. A typical panel includes testosterone, liver function tests, and renal function markers. These results are recorded in a structured table to aid multidisciplinary discussion.

These laboratory results, combined with clinical findings, guide the decision to proceed with imaging and biopsy, forming the foundation of accurate diagnosis and staging.

Imaging Modalities for Precise Staging

Modern imaging is essential for mapping the extent of prostate cancer beyond the prostate gland. Liv Hospital offers a full suite of high‑resolution techniques, each selected based on disease risk and patient factors.

Multiparametric MRI (mpMRI)

• Provides detailed anatomy of the prostate and surrounding tissues.
• Helps identify suspicious lesions for targeted biopsy.
• Assesses extracapsular extension and seminal vesicle invasion.

Bone Scintigraphy and NaF PET/CT

Bone scans detect skeletal metastases, a common site for advanced prostate cancer. NaF PET/CT offers higher sensitivity and is increasingly used for early detection of bone involvement.

Cross‑Sectional Imaging (CT & MRI)

Contrast‑enhanced CT of the abdomen and pelvis evaluates lymph node involvement and potential visceral metastases. Pelvic MRI complements CT by providing superior soft‑tissue contrast for local staging.

Choosing the appropriate imaging sequence is a collaborative decision made by our urologists, radiologists, and oncologists, ensuring that each patient receives the most informative assessment for accurate diagnosis and staging.

Pathology and Gleason Scoring

Definitive diagnosis requires tissue sampling. At Liv Hospital, we perform both systematic and MRI‑targeted biopsies, maximizing detection of clinically significant cancer while minimizing unnecessary cores.

Biopsy Techniques

• Transrectal ultrasound‑guided systematic 12‑core biopsy.
• Transperineal template biopsy for extensive sampling.
• MRI‑fusion targeted biopsy of lesions identified on mpMRI.

Gleason Grade Group System

Pathologists assign a Gleason score based on the architectural pattern of cancer cells. The newer Grade Group system (1–5) simplifies risk communication:

These pathological findings, combined with imaging and laboratory data, complete the diagnosis and staging process, allowing our multidisciplinary tumor board to assign a precise disease stage.

International Staging Systems: TNM and Risk Stratification

Prostate cancer staging follows the American Joint Committee on Cancer (AJCC) TNM framework, complemented by risk stratification models that integrate PSA, Gleason Grade Group, and clinical stage.

TNM Overview

• T (Tumor): Size and extent of the primary tumor (e.g., T1‑T4).
• N (Nodes): Presence or absence of regional lymph node metastasis (N0 vs. N1).
• M (Metastasis): Distant spread, most commonly to bone (M0 vs. M1).

Risk Groups (D’Amico Classification)

The D’Amico system categorizes patients into low, intermediate, or high risk based on three parameters:

By mapping each patient’s data onto both the TNM stage and risk group, our clinicians can predict outcomes, discuss therapeutic options, and set realistic expectations. This dual‑system approach is integral to the comprehensive diagnosis and staging workflow at Liv Hospital.

Personalized Treatment Planning Based on Staging

Once the full diagnostic picture is assembled, a personalized treatment plan is crafted. Staging determines whether a patient is a candidate for curative intent therapies or requires systemic management.

Curative Options for Localized Disease

• Robotic‑assisted radical prostatectomy – precise removal with nerve‑sparing techniques.
• External beam radiation therapy (EBRT) – including intensity‑modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT).
• Brachytherapy – low‑dose‑rate seed implantation for selected low‑risk patients.
• Active surveillance – monitoring low‑risk disease with periodic PSA, MRI, and repeat biopsies.

Systemic Therapies for Advanced Stages

When staging reveals nodal involvement (N1) or distant metastasis (M1), we incorporate systemic treatments such as androgen deprivation therapy (ADT), novel hormonal agents (abiraterone, enzalutamide), chemotherapy, or targeted radionuclide therapy (Radium‑223). Liv Hospital’s oncology team coordinates these modalities with supportive care services, ensuring continuity for international patients.

Multidisciplinary Review Process

Every case is presented at a weekly tumor board that includes urologists, medical oncologists, radiation oncologists, radiologists, pathologists, and nursing specialists. This collaborative review guarantees that the chosen treatment aligns with the patient’s stage, comorbidities, personal preferences, and travel logistics.

Through this rigorous, stage‑driven pathway, Liv Hospital transforms the complex data gathered during diagnosis and staging into a clear, actionable plan that maximizes therapeutic benefit while minimizing unnecessary interventions.

Why Choose Liv Hospital?

Liv Hospital is a JCI‑accredited, internationally focused medical center in Istanbul, offering a seamless experience for patients traveling from abroad. Our dedicated International Patient Services team handles appointments, airport transfers, interpreter support, and comfortable accommodation options, allowing you to focus solely on your health. Backed by state‑of‑the‑art technology, a multilingual staff, and a proven track record in oncology, we deliver high‑quality, patient‑centered care that meets global standards.

Ready to take the next step in your prostate cancer journey? Contact Liv Hospital today to schedule a comprehensive diagnostic evaluation and receive a personalized staging report. Our experts are standing by to guide you through every phase of care, from initial testing to tailored treatment.